Clinical Trial Detail


Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at :

NCT ID NCT03198026
Title Obinutuzumab and Ibrutinib as Front Line Therapy in Treating Patients With Indolent Non-Hodgkin's Lymphomas
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors Sidney Kimmel Cancer Center at Thomas Jefferson University

marginal zone B-cell lymphoma

follicular lymphoma


Ibrutinib + Obinutuzumab

Age Groups: senior | adult
Covered Countries USA

No variant requirements are available.